# Vortioxetine for post-COVID cognitive dysfunction and depressive symptoms: a case report - URL: https://alisanburak.com/en/wcp-2026-posterler/ev0399 - Language: en - Last updated: not specified - Page title: Vortioxetine for post-COVID cognitive dysfunction and depressive symptoms: a case report | WCP 2026 Summary > In a patient with post-COVID cognitive complaints and depressive symptoms, vortioxetine treatment was associated with improvements in depressive symptoms and c… This page was translated automatically from Turkish. [Read the original](https://alisanburak.com/wcp-2026-posterler/ev0399) This page is an AI-assisted Turkish summary of the study presented at the 26th World Congress of Psychiatry. The study belongs to the presenting authors; please refer to the original source when citing it. EV0399 E-PosterPsychopharmacologyCase Report # Vortioxetine for post-COVID cognitive dysfunction and depressive symptoms: a case report VORTIOXETINE IN POST COVID COGNITIVE DYSFUNCTION AND DEPRESSIVE SYMPTOMS A CASE REPORT Presenter: Darko Vlahović Country: Croatia Institution: Sestre milosrdnice University Hospital Center, Department of Psychiatry In a patient with post-COVID cognitive complaints and depressive symptoms, vortioxetine treatment was associated with improvements in depressive symptoms and cognitive performance over a 10-week follow-up and was well tolerated. The poster describes clinical improvement with vortioxetine treatment in a patient with persistent cognitive symptoms (brain fog) and depressive features following COVID-19. The longitudinal clinical course of a 46-year-old man who developed impaired attention, slowed thinking, mental fatigue, reduced work performance, and depressive symptoms following COVID-19 was monitored. Assessment included a psychiatric interview, repeated clinical assessments, monitoring of functioning, and the Digit Symbol Substitution Test (DSST). Vortioxetine was initiated and titrated to 20 mg/day according to tolerability and clinical response. During follow-up, depressive symptoms improved alongside subjective cognitive complaints, and the DSST score increased from 44 at baseline to 51 after 10 weeks of treatment, indicating improvement in attention and processing speed. The patient reported better concentration, less mental fatigue, and increased work productivity and daily functioning, with no clinically significant adverse effects observed. The author notes that vortioxetine may be of interest, particularly when fatigue and functional impairment are prominent, and that its role needs to be clarified through prospective studies. [View the original poster](https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/3) How to cite this study APA 7: Vlahović, D. (2026, September 23-26). Vortioxetine in post covid cognitive dysfunction and depressive symptoms a case report [E-poster]. 26th WPA World Congress of Psychiatry (WCP 2026), Stockholm, Sweden. https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/3 Vancouver: Vlahović D. Vortioxetine in post covid cognitive dysfunction and depressive symptoms a case report [e-poster]. 26th WPA World Congress of Psychiatry (WCP 2026); 2026 Sep 23-26; Stockholm, Sweden. Available from: https://cslide.ctimeetingtech.com/wcp26/attendee/eposter/file/3 Author names and title formatting were generated automatically from the congress system; please check them against the original poster before use. ## On the same topic - [Açığı kapatmak: erişkin DEHB ilacı başlanmadan önce EKG sevk uyumunun iyileştirilmesi, kapalı döngü klinik denetim](https://alisanburak.com/en/wcp-2026-posterler/ev0088) - [Anksiyete bozukluğu olan hastalarda psikobiyotik müdahalesi: ısıl işlem görmüş Lactobacillus paracasei PS23'ün etkilerini inceleyen çift kör randomize kontrollü çalışma](https://alisanburak.com/en/wcp-2026-posterler/ev0126) - [Otizm spektrum bozukluğunda bumetanidin tedavi edici potansiyeli: güncel kanıtlar ve gelecek yönelimleri](https://alisanburak.com/en/wcp-2026-posterler/ev0157) - [Verbaskozid ile otizm spektrum bozukluğu tedavisinin mekanizmaları: ağ farmakolojisi, moleküler yerleştirme ve moleküler dinamik temelli inceleme](https://alisanburak.com/en/wcp-2026-posterler/ev0172) - [Otizm spektrum bozukluğunun çekirdek belirtilerinin tedavisinde kannabidiol: sistematik derleme](https://alisanburak.com/en/wcp-2026-posterler/ev0186) [All WCP 2026 summaries](https://alisanburak.com/en/wcp-2026-posterler) --- Kaynak / Source: https://alisanburak.com/en/wcp-2026-posterler/ev0399 İletişim / Contact: Bağdat Caddesi, Veli Güneysu Apt. No:453 K:4 D:9, Suadiye / Kadıköy, İstanbul · +90 532 642 95 25 · info@alisanburak.com · https://alisanburak.com/bagdat-caddesi-psikoterapi-iletisim